​FORA® Diamond MINI Blood Glucose Monitor Provides Seamless Connection with the Cellnovo System, the First Connected Diabetes Management Platform

ST. GALLEN, Switzerland, December 07, 2018 /PRNewswire/ — ForaCare Suisse AG announced that its FORA® Diamond Mini glucose monitoring device integrates well with the Cellnovo Gen 3 System. The Cellnovo System is the first connected diabetes management platform based on a locked-down AndroidTM smartphone communicating via Bluetooth® Low Energy with a small, discreet micro-pump for insulin delivery. The combination of both products will offer an easy-to-use premium platform for diabetes management.

 

ForaCare is pleased to provide a superior tool that integrates well with the Cellnovo Gen 3 to provide an advanced and complete technology solution for diabetes patients,” said Ty-Minh Tan, CEO of ForaCare Suisse AG.

The FORA® Diamond MINI is a Bluetooth® glucometer that connects with the Cellnovo Gen 3 system via Bluetooth® Low Energy. The Diamond MINI has been sold in nine countries including France, Italy, Greece, The Netherlands, Portugal, Middle East (UAE), Czech Republic, South Africa, and Switzerland. Cellnovo has an established international commercial network in 10 countries: United Kingdom, France, Italy, The Netherlands, Spain, Australia, New Zealand, Israel, Greece and Cyprus.

 

FORA® Diamond MINI works well with the Cellnovo system that includes a built-in blood glucose app that integrates Bluetooth®-enabled blood glucose meters that are compatible with the system. The FORA Diamond MINI’s features include an easy-to-carry lightweight, pocketsize design with a sleek modern appearance. Most importantly, the FORA Diamond MINI is highly accurate and precise (the device has fulfilled EN ISO 15197:2015 requirements). It has a built-in Bluetooth® BLE (V4.0) chip and a convenient rechargeable battery. To learn more, review the FORA® Diamond MINI product at http://forafullcare.com/diamond/Diamond_mini_MeterOverview.html.

 

About FORA® devices: 

All ForaCare monitoring devices are validated as highly accurate in the industry and provide superior quality directly to consumers. FORA® Blood Glucose Monitors are validated according to the requirements of the ISO 15197:2013 and EN ISO 15197:2015.

 

ForaCare devices comply with the latest ISO standards and have successfully completed third party validations:

* FORA® Diamond MINI is clinically validated by AMCR Institute in the US and is proven to meet accuracy and precision standards of the ISO 15197:2013 and EN ISO 15197:2015; in addition, Diamond MINI also meets the full requirements of the EN ISO 15197:2015, certified by TÜV SÜD in 2015.​​

* The latest FORA® 6 Connect comes with gold test strips and uses advanced 5-electrode technology which features higher accuracy and better precision specially designed for advanced diabetes management. FORA® 6 Connect has also met the standards of EN ISO 15197:2015, confirmed by TÜV SÜD in 2018. In addition, the studies done by IDT and AMCR Institute have proven that the FORA® 6 Connect’s performance has fulfilled accuracy and precision standards of ISO 15197:2013 and EN ISO 15197:2015.

ForaCare offers CE certified innovative health monitoring devices that provide simple connection to the FORA® healthcare system. For more information, please visit www.foracare.ch.

 

About ForaCare Suisse AG: www.foracare.ch/about-foracare

 

About Cellnovo (Euronext: CLNV)

Cellnovo Group is a global innovative medical technology company supporting the needs and desires of people with type 1 diabetes. Cellnovo has developed and markets a novel diabetes management system, which is a connected platform that aims to make life easier for people with type 1 diabetes. Cellnovo’s insulin delivery system comprises of a locked-down AndroidTM smartphone that communicates via BluetoothÒ with a discreet, wearable micro-pump. This unique system allows optimal management of insulin dosing and delivery while ensuring freedom of movement and peace of mind. Thanks to the transmission of data in real time, the patient’s status can be seamlessly monitored by family members and healthcare professionals. Cellnovo is currently participating in several major Artificial Pancreas projects with TypeZero, PEPPER and Diabeloop, to develop fully automated, closed-loop insulin delivery systems.

 

For more information go to www.cellnovo.com

 

Contact:

Dr. Elena Birrer

+41-71-220-1001

Email: elena.birrer@foracare.com

Website: http://www.foracare.ch/

Facebook: ForaCare Suisse AG

Youtube : ForaCare Wireless Telehealth System

COPYRIGHT © 2019 ForaCare Suisse AG. All rights reserved.